Navigation Links
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
Date:11/6/2008

- Third quarter net loss narrows on higher revenue due to Roche milestone -

BRISBANE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2008. InterMune reported a net loss for the third quarter of 2008 of $12.5 million, or $0.32 per share, compared with a net loss of $23.1 million, or $0.66 per share, in the third quarter of 2007.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Third quarter and recent events have highlighted our significant progress on pirfenidone and ITMN-191. On October 16, Shionogi's Japanese NDA for pirfenidone was approved, making pirfenidone the first drug approved for idiopathic pulmonary fibrosis (IPF) in any major market in the world. We reported exceptional patient retention in our Phase 3 CAPACITY program for pirfenidone in IPF and we set the expectation for announcement of top-line results from CAPACITY in January or February of 2009. With ITMN-191, we remain committed to announcing top-line results of our triple combination study of ITMN-191 with Pegasys(R) (pegylated interferon alfa-2a) and Copegus(R) (ribavirin) during this quarter."

Results for Third Quarter 2008

InterMune reported total revenue in the third quarter of 2008 of $23.3 million, compared with total revenue of $11.4 million in the third quarter of 2007. Total revenue in the third quarter of 2008 primarily consisted of revenue from the collaboration with Roche for the development of protease inhibitors, including ITMN-191 (R7227), which totaled $15.8 million in the third quarter of 2008, compared with $0.8 million in the same quarter of 2007. Third quarter 2008 collaborati
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... the leader in quantitative immunohistochemistry, announces the application ... messenger RNA in tissue.  AQUA technology enables robust ... this new work extends the platform,s capabilities beyond ... AQUA technology was invented to ...
... A team of Australian scientists has identified new genes that ... cancer. The discovery has the potential to underpin ... stages of bowel cancer. This test could potentially save thousands ... at risk to have a colonoscopy. The research[1] ...
... The " Anesthesia Drugs Market ... and studies the U.S. market for intravenous anesthesia drugs with special focus ... & import system for controlled substances in U.S. and U.S. market entry ... of   " Anesthesia Drugs Market (2011 ...
Cached Biology Technology:AQUA® Technology Uses Extend Beyond Protein: Effective measurement of messenger RNA now demonstrated 2AQUA® Technology Uses Extend Beyond Protein: Effective measurement of messenger RNA now demonstrated 3Australian Discovered Biomarkers Map Path to New Blood Test for Bowel Cancer 2Australian Discovered Biomarkers Map Path to New Blood Test for Bowel Cancer 3Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 2Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 3
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... day each month stood out among other religious practices ... Latter-Day Saints (LDS or Mormons), who have lower rates ... the American Heart Associations Scientific Sessions 2007., People who ... appeared to also hold true in non-LDS people who ...
... e-Smart Technologies, Inc.,(Pink Sheets: ESMT); ("e-Smart") with its ... the "Company") is,pleased to announce that the United ... for the Company,s cutting edge, intelligent biometric,identification card ... States Patent and Trademark Office,issued Patent No. 7,278,025, ...
... bird brains can get to know an entire continent -- ... so, suggests a Princeton research team. The scientists ... to their winter nesting grounds even after being thrown off ... compensate for the displacement. However, similarly displaced juvenile birds, which ...
Cached Biology News:People who skip meals: are they better off? 2People who skip meals: are they better off? 3Patent Issued for e-Smart Technologies, Inc.'s First Biometric Match-on-Card Technology 2Patent Issued for e-Smart Technologies, Inc.'s First Biometric Match-on-Card Technology 3For migrating sparrows, kids have a compass, but adults have the map 2
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
...
... SDS and Non-ionic Detergent Removal ... , Very selective, virtually no cross-reactivity with ... and discard pellet , Economical new ... , Detergents can often interfere with protein ...
Biology Products: